Pneumococcal virulence factors in community-acquired pneumonia.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
10
3
2020
medline:
4
2
2021
entrez:
10
3
2020
Statut:
ppublish
Résumé
This manuscript reviews the recent literature related to new developments in the understanding of existing and novel virulence factors of the pneumococcus that are of potential importance in the development of novel preventive and therapeutic strategies. The pneumococcal capsule and pneumolysin have long been recognized as being two of the most prominent virulence factors, with much recent research having revealed previously unrecognized mechanisms by which they contribute to the pathogenesis of infection. Although the pneumococcal capsule has been considered a sine qua non for virulence, the emergence of pathogenic nonencapsulated strains with newly recognized virulence determinants has also been described. Not unexpectedly, but of concern, nonencapsulated strains are unaffected by current pneumococcal vaccines. This, together with the finding of novel virulence factors, as well as new mechanisms of pathogenicity of established virulence determinants, underscores the resilience of the pneumococcus in confronting challenges in its environment, most importantly those posed by antibiotics and vaccines. Recent advances in the understanding of pneumococcal virulence factors provide potential opportunities for the development of novel putative therapeutic or preventive strategies.
Identifiants
pubmed: 32149750
doi: 10.1097/MCP.0000000000000674
pii: 00063198-202005000-00007
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Pneumococcal Vaccines
0
Streptolysins
0
Virulence Factors
0
plY protein, Streptococcus pneumoniae
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-231Références
GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018; 18:1191–1210.
Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol 2018; 16:355–367.
Brooks LRK, Mias GI. Streptococcus pneumoniae's virulence and host immunity: Aging, diagnostics, and prevention. Front Immunol 2018; 9:1366.
Ulrych A, Petráčková D, Goldová J, et al. PynA is a pyrimidine 5’-nucleotidase that functions as an antimutator protein in Streptococcus pneumoniae. FEBS J 2020; 287:267–283.
Pelletier A, Freton C, Gallay C, et al. The tyrosine-autokinase UbK is required for proper cell growth and cell morphology of Streptococcus pneumoniae. Front Microbiol 2019; 10:1942.
Gullett JM, Cuypers MG, Frank MW, et al. A fatty acid-binding protein of Streptococcus pneumoniae facilitates the acquisition of host polyunsaturated fatty acids. J Biol Chem 2019; 294:16416–16428.
Yang XY, He K, Du G, et al. Integrated translatomics with proteomics to identify novel iron-transporting proteins in Streptococcus pneumoniae. Front Microbiol 2016; 7:78.
Yang XY, Li N, Xu JY, et al. Lipoprotein SPD_1609 of Streptococcus pneumoniae promotes adherence and invasion to epithelial cells contributing to bacterial virulence. Front Microbiol 2019; 10:1769.
Becke TD, Ness S, Kaufmann BK, et al. Pilus-1 backbone protein RrgB of Streptococcus pneumoniae binds collagen I in a force-dependent way. ACS Nano 2019; 13:7155–7165.
Nagai K, Domon H, Maekawa T, et al. Pneumococcal DNA-binding proteins released through autolysis induce the production of proinflammatory cytokines via toll-like receptor 4. Cell Immunol 2018; 325:14–22.
Radhakrishnan D, Yamaguchi M, Kawabata S, Ponnuraj K. Streptococcus pneumoniae surface adhesin PfbA and its interaction with erythrocytes and hemoglobin. Int J Biol Macromol 2018; 120:135–143.
Yamaguchi M, Hirose Y, Takemura M, et al. Streptococcus pneumoniae evades host cell phagocytosis and limits host mortality through its cell wall anchoring protein PfbA. Front Cell Infect Microbiol 2019; 9:301.
Beiter K, Wartha F, Albiger B, et al. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol 2006; 16:401–407.
Wartha F, Beiter K, Albiger B, et al. Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell Microbiol 2007; 9:1162–1171.
Martinez PJ, Farhan A, Mustafa M, et al. PspA facilitates evasion of pneumococci from bactericidal activity of neutrophil extracellular traps (NETs). Microb Pathog 2019; 136:103653.
Bradshaw JL, Pipkins HR, Keller LE, et al. Mucosal infections and invasive potential of nonencapsulated Streptococcus pneumoniae are enhanced by oligopeptide binding proteins AliC and AliD. MBio 2018; 9: pii: e02097-17.
pii: e02097-17
Paton JC, Trappetti C. Streptococcus pneumoniae capsular polysaccharide. Microbiol Spectr 2019; 7: GPP3-0019-2018.
Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, present, and future. Clin Micro Rev 2015; 28:871–899.
Van Tonder AJ, Gladstone RA, Lo SW, et al. Putative novel cps loci in a large global collection of pneumococci. Microb Genom 2019; 5: doi: 10.1099/mgen.0.000274.
doi: 10.1099/mgen.0.000274
Middleton DR, Paschall AV, Duke JA, Avci FY. Enzymatic hydrolysis of pneumococcal capsular polysaccharide renders the bacterium vulnerable to host defense. Infect Immun 2018; 86: pii: e00316-18.
pii: e00316-18
Nahm MH, Brissac T, Killian M, et al. Pneumococci can become virulent by acquiring a new capsule from oral streptococci. J Infect Dis 2019; pii jiz456doi: 10.1093/infdis/jiz 456. [Epub ahead of print].
doi: 10.1093/infdis/jiz
Ye W, Zhang J, Shu Z, et al. Pneumococcal LytR protein is required for the surface attachment of both capsular polysaccharide and teichoic acids: essential for pneumococcal virulence. Front Microbiol 2018; 9:1199.
Dennis EA, Coats MT, Griffin S, et al. Hyperencapsulated mucoid pneumococcal isolates from patients with cystic fibrosis have increased biofilm density and persistence in vivo. Pathog Dis 2018; 76:fty073.
Li J, Zhang JR. Phase variation of Streptococcus pneumoniae. Microbiol Spectr 2019; 7: GPP3-0005-2017.
Leonard A, Lalk M. Infection and metabolism – Streptococcus pneumoniae metabolism facing the host environment. Cytokine 2018; 112:75–86.
Nakamya MF, Ayoola MB, Park S, et al. The role of cadaverine synthesis on pneumococcal capsule and protein expression. Med Sci (Basel) 2018; 6: pii: E8.
pii: e8
Ayoola MB, Shack LA, Nakamya MF, et al. Polyamine synthesis effects capsule expression by reduction of precursors in Streptococcus pneumoniae. Front Microbiol 2019; 10:1996.
Troxler LJ, Werren JP, Schaffner TO, et al. Carbon source regulates polysaccharide capsule biosynthesis in Streptococcus pneumoniae. J Biol Chem 2019; 294:17224–17238.
Carvalho SM, Kloosterman TG, Manzoor I, et al. Interplay between capsule expression and uracil metabolism in Streptococcus pneumoniae D39. Front Microbiol 2018; 9:321.
Bradshaw JL, McDaniel LS. Selective pressure: rise of the nonencapsulated pneumococcus. PloS Path 2019; 15:e1007911.
Mohale T, Wolter N, Allam M, et al. Genomic differences among carriage and invasive nontypeable pneumococci circulating in South Africa. Microb Genom 2019; 5: doi: 10.1099/mgen.0.000299.
doi: 10.1099/mgen.0.000299
Nel JG, Durandt C, Mitchell TJ, et al. Pneumolysin mediates platelet activation in vitro. Lung 2016; 194:589–593.
Nel JG, Durandt C, Theron AJ, et al. Pneumolysin mediates heterotypic aggregation of neutrophils and platelets in vitro. J Infect 2017; 74:599–608.
Nel JG, Theron AJ, Durandt C, et al. Pneumolysin activates neutrophil extracellular trap formation. Clin Exp Immunol 2016; 184:358–367.
Anderson R, Nel JG, Feldman C. Multifaceted role of pneumolysin in the pathogenesis of myocardial injury in community-acquired pneumonia. Int J Mol Sci 2018; 19: pii: E1147.
pii: e1147
Feldman C, Normark S, Henriques-Normark B, Anderson R. Pathogenesis and prevention of risk of cardiovascular events in patients with pneumococcal community-acquired pneumonia. J Intern Med 2019; 285:635–652.
Subramanian K, Neill DR, Malak HA, et al. Pneumolysin binds to the mannose receptor C type 1 (MRC-1) leading to anti-inflammatory responses and enhanced pneumococcal survival. Nat Microbiol 2019; 4:62–70.